Cue Biopharma Inc (CUE)
1.705
+0.22
(+14.81%)
USD |
NASDAQ |
Nov 05, 16:00
1.74
+0.04
(+2.05%)
After-Hours: 20:00
Cue Biopharma Debt to Equity Ratio: 0.289 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.289 |
| March 31, 2024 | 0.2399 |
| December 31, 2023 | 0.2202 |
| September 30, 2023 | 0.2138 |
| June 30, 2023 | 0.2191 |
| March 31, 2023 | 0.1825 |
| December 31, 2022 | 0.1522 |
| September 30, 2022 | 0.1961 |
| June 30, 2022 | 0.1659 |
| March 31, 2022 | 0.1525 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.289
Maximum
Jun 2024
0.1069
Average
0.1522
Median
Dec 2022
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.1098 |
| Arbutus Biopharma Corp | 0.00 |
| GlycoMimetics Inc | -- |
| FibroGen Inc | -0.3119 |
| Cidara Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 42.33M |
| Total Liabilities (Quarterly) | 20.71M |
| Shareholders Equity (Quarterly) | 21.62M |
| Current Ratio | 2.060 |
| Net Debt Paydown Yield | 1.26% |